Amylin Analog Obesity Therapeutics Market to Reach $1.3 Billion by 2036

The amylin analog obesity therapeutics market is poised for substantial growth, with projections indicating an increase from $140 million in 2026 to approximately $1.3 billion by 2036. This growth is driven by the anticipated approval of amylin-containing medications, which are currently progressing through late-stage clinical trials. The first of these, CagriSema, is under review by the U.S. FDA following promising results from the REDEFINE 1 trial, where participants experienced an average weight loss of 22.7% compared to 2.3% for the placebo group.

Historically, the market for amylin analogs has been limited, with no products yet available for routine sale. However, as clinical trials yield positive results and regulatory approvals are granted, the market is expected to expand rapidly. The competitive landscape is also evolving, with significant pressure on pricing and efficacy as new products enter the market. Eli Lilly's eloralintide has shown up to 20.1% weight loss in a Phase 2 study, further validating the potential of amylin-based therapies.

Key market trends indicate that selective amylin analogs will dominate the market, accounting for 42.5% of the molecule types by 2026. The once-weekly injection format is expected to lead dosing frequency at 42.9%, aligning with existing patient treatment routines. Additionally, monotherapy is projected to be the leading therapy setting, comprising 56% of the market, as healthcare providers explore effective standalone treatments before considering combinations with other medications.

Regionally, Vietnam, Brazil, and the USA are identified as the fastest-growing markets for amylin analogs, with Vietnam leading at a projected CAGR of 30.8%. This growth is attributed to rising obesity rates and a growing demand for effective weight management solutions. The World Health Organization has reported that approximately 940 million adults worldwide were living with obesity in 2024, highlighting the urgent need for effective treatments.

Looking ahead, the approval of amylin products will be crucial for market expansion. Coverage decisions by public payers will significantly impact patient access to these therapies. As the market evolves, it is expected that amylin analogs will initially be adopted as add-ons or alternatives to existing treatments, rather than as standalone options. The timeline for major clinical readouts and regulatory decisions will shape the future landscape of the amylin analog obesity therapeutics market.